Back to dataset
Inflammatory bowel disease national clinical audit of biological therapies (2016)Data field description file biological therapies audit 2016
You're previewing the first 4 rows of this file.
Download this file| Column 1 | Column 2 | Column 3 | Column 4 | Column 5 | Column 6 | Column 7 | Column 8 | Column 9 |
|---|---|---|---|---|---|---|---|---|
| Health board / Trust name | Sitename | Participation status | Number of patients entered to the audit between 1 March 2015 and 29 February 2016 | Number of patients with adequate pre-treatment screening | Number of patients with documented follow-up at 3 months | Number of patients with documented disease activity index at 3 months | Number of patients being treated with infliximab (Remicade) | Number of patients being treated with infliximab biosimilars (Inflectra / Remsima) |
| Name of Health Board / Trust | Name of site | Did site participate | Number of patients entered to the audit between 1 March 2015 and 29 February 2016 | Percentage of patients with adequate pre-treatment screening | Percentage of patients with documented follow-up at 3 months | Percentage of patients with documented disease activity index at 3 months | Percentage of patients being treated with infliximab (Remicade) | Percentage of patients being treated with infliximab biosimilars (Inflectra / Remsima) |
| text | text | text | integer | Percentage (integer) | Percentage (integer) | Percentage (integer) | Percentage (integer) | Percentage (integer) |
| text | text | text | 0 | 0% (0/0) | 0% (0/0) | 0% (0/0) | 0% (0/0) | 0% (0/0) |